-
The ECG shown above was a baseline tracing obtained during the initial visit with a new primary care provider. How would you interpret the tracing? What do you suspect happened in the past?
-
The women's health initiative (WHI) provided convincing evidence that the use of estrogen plus progesterone (E+P) in postmenopausal women is associated with an increased risk of breast cancer.
-
Eltrombopag is a thrombopoietin (TPO) receptor agonist approved by the FDA for the treatment of thrombocytopenia.
-
In older women and men, all low-trauma fractures were associated with increased mortality risk for at least 5 years. Subsequent fracture increased that risk.
-
For persons aged 65 or older in the United States, congestive heart failure (CHF) remains the most common diagnosis for hospital admission.
-
Evaluation of the clinical course of the 21,094 eligible U.S. male physicians in the Physicians' Health Study revealed that an elevated BMI in both pre-obese and obese subjects was associated with an increased risk of CHF and that vigorous physical activity was associated with a decreased risk of CHF.
-
Proton pump inhibitors given concomitantly with clopidogrel administered after acute myocardial infarction appear to diminish the beneficial effects of clopidogrel, thus increasing the risk of re-infarction.
-
-
Forty-one women with symptomatic, histologically proven endometriosis (Stages 1-4) were randomized to receive either a contraceptive implant (Implanon®) or depot medroxyprogesterone acetate (DMPA).
-
In this issue: Individualization of therapy with pharmacogenetics; the rate vs rhythm debate; the FDA's Risk Evaluation and Mitigation Strategy; FDA actions.